Cardiovascular Risk Management in CKD

Statin Therapy

• The Kidney International guidelines recommend initiating statin therapy concurrently in elderly patients with stage 3 CKD, as this population requires cardiovascular risk reduction (strong recommendation, 1A evidence) 1, 2, 3
• Adults ≥50 years with eGFR <60 ml/min/1.73 m² should be prescribed a statin or statin/ezetimibe combination (strong recommendation, 1A evidence) 1, 2, 3
• The Kidney International guidelines suggest maximizing LDL cholesterol reduction to achieve the largest treatment benefits in CKD patients 2, 3
• Rosuvastatin should be started at 5 mg daily in patients with severe renal impairment, not exceeding 10 mg daily 3